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A B S T R A C T
Objective: Penetrance, predictive value and female patients' perspectives on genetic testing were evaluated
among Finnish patients with acute porphyria. We conducted a retrospective study to evaluate prognosis among
at-risk female family members depending on the primary method of diagnosis.
Methods: The penetrance was calculated among 23 genetically heterogeneous families selected from the Finnish
porphyria registry (n = 515, AIP 333; VP 182). We included kindreds with ≥9 patients in a family (range 9–23
patients, total 216 AIP; 129 VP). In 2015, the registry included 164 living female subjects between 14 and
85 years of age. A questionnaire was sent to 143 women, of whom 107 (75%, AIP 67; VP 40) replied. Female at-
risk relatives (AIP 54; VP 30) were divided into two groups based on the primary method of diagnosis: mutation
analysis (Group A, n = 40) or biochemical analysis (Group B, n = 44).
Results: Mean penetrance for all acute symptoms was 35% among AIP and 40% among VP families. In both study
groups, the penetrance was higher among female (AIP 50%; VP 44%) than male patients (AIP 17%; VP 33%).
Penetrance for hospitalized attacks was 30% among AIP families (range 10–80%, for women 41%) and 25% in
VP (range 0–50%, for women 27%) demonstrating wide variations among families even with the similar gen-
otype. Acute porphyria was diagnosed at the median age of 26 years (range 0–76 years) among female patients,
commonly after the onset of acute symptoms. Diagnostic delay was an average of 7.4 years (range 1–30 years).
Acute symptoms occurred at the median age of 24 years (range 10–57 years) and the first hospitalization at the
median age of 26.5 years (range 15–57 years). At the onset of symptoms, 38% of the women were ≤ 20 years of
age. According to the life table analysis, acute attacks occurred mainly during the following five years after the
diagnosis and the attack risk diminished after 35 years of age. The annual risk for hospitalization due to an acute
attack during fertile years was lower in Group A than Group B (0.002 vs. 0.010, p = .018), but the risk of all
subsequent acute symptoms did not diminish (Group A 0.017 vs. Group B 0.019, p = .640). The cumulative risk
of acute symptoms among asymptomatic patients at the time of diagnosis was 26.7% for Group A and 58.3% for
Group B. The cumulative risk of the first subsequent attack requiring hospitalization after the diagnosis among
all at-risk relatives was similarly less frequent in Group A than in Group B (OR 0.180; 95% CI 0.041–0.789,
p = .041). If attacks were followed among symptomatic patients only, attack-free years were more frequent in
Group A than in Group B. Patients preferred genetic screening before puberty to minimize the risk of acute
symptoms and genetic discrimination was rare. 44% of the patients reported social, psychological or physical
impairment due to acute hepatic porphyria, emphasizing the importance of supporting patients' emotional and
resilience capacity.
Conclusions: Among female at-risk relatives the annual risk for hospitalization due to an acute attack is < 1%
and for acute symptoms < 2% during the fertile years. Genetic testing of relatives diminishes the risk of acute
attacks. Diagnosis before symptom onset is key for subjects to remain asymptomatic during follow-up, and
genetic screening should be done earlier than currently.
1. Introduction
Acute porphyrias are inherited metabolic diseases that mainly
exhibit an autosomal dominant pattern of inheritance caused by partial
deficiencies of heme biosynthesis related enzymes [1–3]. They manifest
with acute attacks including a combination of autonomic neuropathy
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(abdominal pain, palpitation), peripheral neuropathy (pain in ex-
tremities and back, muscle weakness) and encephalopathy (insomnia,
fatigue, restlessness) [4,5]. This is caused by accumulation of porphyrin
precursors, which originate mainly from the liver [6]. Acute attacks are
commonly induced by multiple exogenous and endogenous factors,
which up-regulate ALAsynthase-1, the rate-limiting enzyme in the heme
biosynthetic pathway.
Eight genes in the heme biosynthesis are well known. More than
400 mutations have been reported to cause acute intermittent por-
phyria (AIP, MIM #176000) and 177 mutations variegate porphyria
(VP, MIM #176200) [7,8]. In Finland, the genetic background for acute
porphyrias has been heterogeneous, including the major mutation
among VP patients [9,10]. Patients with other acute porphyrias, ALAD
deficiency porphyria (MIM #125270) and hereditary coproporphyria
(HCP, MIM #121300), are more rare and have not been identified in
Finland to date.
In 2013, the incidence and prevalence have been evaluated in
Europe as being 0.13 and 5.9 per million inhabitants for AIP and 0.08
and 3.2 per million inhabitants for VP, respectively [11]. Although the
inheritance of mutations causing acute porphyria is equal between men
and women [12,13], the vast majority of the porphyria patients with
clinical manifestations are women [9,13]. This is commonly due to
hormonal changes during the luteal phase of the menstrual cycle, which
together with other precipitating factors such as fasting, infection, al-
cohol and certain drugs, may induce attacks [14].
Penetrance has varied from 10% to 42% between clinical reports,
depending on the inclusion criteria of the clinical outcome and the
number of members studied within the families with acute porphyria
[9,11,15,16]. A population-based study has suggested the penetrance
for acute attacks is as low as 1% for the mutation carriers [17].
Acute attacks have often been misdiagnosed since symptoms of
acute porphyria mimic other, more common, causes of abdominal pain
or confusion. Attacks can be potentially fatal, with 10% mortality, if
undiagnosed [9,14,18,19]. Accurate analysis of porphyrin metabolites
during an acute attack is crucial, allowing the early start of an appro-
priate treatment regimen, which commonly results in the full recovery
of the patient [4,20–22]. Genetic testing and counseling of the patients
and at-risk family members have decreased the morbidity and severity
of an acute attack mainly due to early diagnosis of acute porphyria and
avoidance of inaccurate treatment [9,10].
Although genetic testing has been available for more than three
decades for acute porphyrias, practical guidelines are scarce [23–25].
Despite the clinical benefits of DNA analysis, it may lead to un-
predictable disadvantages such as altering family dynamics, psycholo-
gical disturbance and insurance or employment discrimination [26].
In this study, we have used the Finnish patient registry for acute
porphyria as a backbone for analyzing penetrance among Finnish pa-
tients with AIP and VP. We selected a subgroup of 107 female patients
to evaluate their morbidity and the predictive value of genetic testing.
A questionnaire was used to elucidate female patients' perspectives on
genetic testing and diagnosis, and their experience in the health care
system.
2. Subjects and methods
2.1. Patients
We have kept a registry in the Helsinki University Hospital (HUH)
that includes all Finnish patients known to have porphyria since 1966
[14,27]. Currently, there are 333 patients with AIP and 182 patients
with VP, of whom the study group was set to include women at
14–85 years of age. Of the 182 living female subjects, 164 patients were
within this age group in 2015. A questionnaire designed for acute
porphyria was sent to 143 patients (91 AIP, 52 VP), of whom 67 AIP
patients (74%) and 40 VP patients (77%) were enrolled for the study
during 2015 (Fig. 1).
Informed consent was obtained from all study patients, and also
from their guardians in case of adolescents. The Ethical Committee of
the Department of Medicine, HUH, approved the study protocol.
2.2. Diagnosis of acute porphyria
Since 1989, mutation analysis has been performed in 358 family
members and patients with AIP and 203 family members and patients
with VP. 168 mutation positive patients with AIP (47% of family
members studied) were identified within 39 families representing 27
mutations in the porphobilinogen deaminase gene (PBGD; also known
as hydroxymethylbilane synthase, HMBS). 115 mutation positive pa-
tients with VP (57% of all family members studied) represented 25
families and 11 different mutations in the protoporphyrinogen oxidase
(PPOX) gene.
The diagnosis of AIP was based either on mutation analysis
(n = 168) or typical clinical symptoms associated with elevated por-
phobilinogen (PBG) and delta-aminolevulinic acid (DALA) levels, low
erythrocyte PBGD activity, typical plasma fluorescence emission spec-
trum (619 mm) and/or pedigree analysis (n = 165). Two subjects were
excluded due to inadequate biochemical analysis.
The diagnosis of VP was based either on mutation analysis
(n = 115) or characteristic clinical symptoms with increased excretion
of fecal protoporphyrin, typical plasma fluorescence emission spectrum
(624 mm), low lymphocyte PPOX activity and/or pedigree analysis
(n = 67).
2.3. Biochemical and mutation analyses
Urinary DALA and PBG were measured using a Bio-Rad (USA)
column test [28]. Determinations of urinary excretion of uro- and co-
proporphyrin and fecal excretion of copro- and protoporphyrin were
performed according to Rimington [29] and Holti et al. [30] until 1988,
and thereafter using high-pressure liquid chromatography (HPLC)
(Varian Inc., US) [31,32]. Plasma porphyrin spectrum was determined
with a characteristic fluorescence emission spectrum, 619 nm for AIP
and 624 nm for VP [33,34]. Enzyme activity was assayed in AIP as
PBGD activity [35] and in VP patients as PPOX activity [36].
Mutations found in the Finnish families with acute porphyria have
been reported elsewhere [10,37]. In family screening, mutation ana-
lysis was performed by isolating DNA from leukocytes, which was
amplified using the polymerase chain reaction (PCR) -technique and
analyzed using restriction digestion, and/or by direct sequencing.
Analyses were repeated at least twice for each sample in the presence of
negative and positive controls.
2.4. Sources of information
Information about clinical manifestations, biochemical and genetic
analysis was obtained from medical reports and our registry. The
questionnaire was designed to obtain information about age at diag-
nosis and onset of symptoms, morbidity, and experiences of standard of
care related to porphyria. In addition, the questionnaire inquired into
patients' perspectives on genetic screening, genetic counseling and
avoidance of precipitating factors as well as the disadvantages con-
cerning an inherited disease.
The severity of clinical symptoms was classified as follows:
1) An acute attack was defined as typical acute symptoms of porphyria
such as abdominal pain or pain in the extremities or back associated
with autonomic dysfunction, polyneuropathy and mental symptoms
in patients with at least a four-fold increase of urinary PBG excretion
requiring hospitalization [20].
2) Porphyria-associated acute symptoms were similar but treated at
home with symptomatic treatment and commonly no biochemical
analysis had been done.
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3) Recurrent attacks were characterized by at least four attacks yearly
requiring hospitalization during the follow-up period.
Skin symptoms in VP were characterized as slowly healing blisters
and erosions with crusting and scarring, and excessive skin fragility in
solar-exposed areas such as the face and dorsal side of the hands
[10,38].
2.5. Statistical methods
The chi-square test was used for comparison of categorical vari-
ables. Continuous variables were analyzed using Mann-Whitney U test
when two groups were compared. Logistic regression was employed to
evaluate the association between outcome variables and covariates.
Statistical calculations were performed with SPSS version 25 (2017).
P < .05 was chosen as the level of statistical significance.
3. Results
3.1. Penetrance of AIP and VP
The penetrance was calculated using female and male patient data
from the Finnish porphyria registry. The 23 families selected (AIP,
n = 14; VP, n = 9) included ≥9 patients in a family (Tables 1 and 2).
Mean penetrance for all acute symptoms was 35% among AIP families
and 40% among VP families (p = .583) (Fig. 2). In both study groups,
the penetrance was higher among female (AIP 50% and VP 44%,
p = .603) than male patients (AIP 17% and VP 33%, p = .076), but no
significant difference was found between AIP or VP patients.
If the penetrance was calculated only for acute attacks that needed
hospitalization, the mean penetrance for AIP patients was 30% (range
10–80%) and 25% (range 0–50%) for VP patients (p = .426). The ratio
of female to male patients was higher in AIP (41% vs. 17% p = .0047)
but not in VP (27% vs. 22% p = .653).
Penetrance for skin symptoms in VP patients was 30% (34% female,
27% male) but a wide variation among families could be detected
(Fig. 2e). Interestingly, this variation could also be seen in 7 (103 pa-
tients) of 11 VP-families with the Finnish major mutation (c. C454T, p.
R152C) both in acute (range 30–70%) as well as in skin symptoms
(range 10–70%).
Fig. 2a and c demonstrate the within-family proportion of acute at-
tacks in patients with AIP and VP. A penetrance of > 50% was noted in
AIP families with mutations c.1073delA, c.C76T (p.R26C) and c.G593A
(p.W198X) in contrast to the lowest penetrance (≤20%) in families with
mutations c.G33T, c.C499T (p.R167W), c.C517T (p.R173W) and c.C673G
(p.R225G). In VP families ≥50% penetrance was associated with the
mutation c.C454T (p.R152C), but also the lowest ≤20% penetrance was
associated with the mutations c.C454T (p.R152C), c.C35T (p.I12T), and
c.G338C (del exon 4). High penetrance (≥70%) of acute attacks was as-
sociated with families diagnosed and treated before 1980.
Fig. 1. Graphical presentation of the subjects enrolled to the study.
Table 1
Mutations and clinical characteristics in AIP families (including index cases).
Mutation Outcome No. of Patients/Total Gender All acute symptoms Mild to moderate acute symptoms Acute attacks
n n % F M F M F M F M
c. G33T Splicing defect 4 22 18.2 10 12 2 2 – – 2 2
c. 33 + 3G > T Retention of 67 bp fragment intron 1 3 10 30 4 6 – 3 – – – 3
c. C76T p. R26C 6 10 50 6 4 5 1 1 – 4 1
c. InsAlu333 Frameshift 6 16 31.3 10 6 6 – 1 – 5 –
c. A293G p. K98R 4 11 36.4 5 6 3 1 – – 3 1
c. C346T p. R116W 5 21 23.8 10 11 3 2 – – 3 2
c. C445T p. R149X 12 21 47.6 14 7 10 2 2 – 8 2
c. C499T p. R167W 2 11 18.2 5 6 2 – – – 2 0
c. C499T p. R167W 1 18 5.56 10 8 1 – – – 1 –
c. C517T p. R173W 6 23 17.4 15 8 10 – 6 – 4 0
c. G593A p. W198X 9 12 75 5 7 5 4 – – 5 4
c. C673G p. R225G 5 17 17.6 8 9 5 – 2 – 3 –
c. C673T p. R225X 8 15 33.3 8 7 6 2 3 – 3 2
c. 1073delA Frameshift 5 9 55.6 7 2 5 – – – 5 –
Total 76 216 117 99 63 17 15 48 17
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3.2. Clinical manifestations of acute porphyria among fertile women
The study group consisted of 107 Finnish female patients within the
age group of 15–85 years. Clinical manifestations were evaluated
during the reproductive years (12–49 years of age), during which the
risk for acute symptoms is at the highest. Average follow-up time from
the diagnosis was 26 years (range 0–60 years, median 26.5 years).
66% of the patients reported porphyria-associated acute symptoms
during the mean follow-up of 32.6 years and 34% patients no acute
symptoms during the mean follow-up of 28.5 years (Fig. 3). 39% of the
patients suffered acute attacks resulting in hospitalization, of whom
57% suffered repeated attacks. 27% of the subjects reported only mild
to moderate acute symptoms, with no hospitalization. 53% of patients
with VP reported skin symptoms.
Mild to moderate acute symptoms and acute attacks requiring
hospitalization were equally frequent in VP and AIP. Patients with VP
reported fewer subsequent attacks, and only patients with AIP had re-
current attacks. Attack-free follow-up within the fertile years was
compared between patients with AIP and VP using Cox regression
survival analysis. The hazard ratios for both acute attacks requiring
hospitalization and acute porphyria associated mild to moderate
symptoms were comparable between AIP and VP (p = .264; p = .488).
Since no statistical difference was observed, both patient groups were
analyzed as one (Table 3).
3.3. Optimal timing of diagnosis
Acute porphyria was diagnosed at the median age of 26 years (range
0–76). Only 2% of the subjects were diagnosed ≤1 year of age (n = 2)
and 19% ≤ 15 years of age (n = 20). 53% of the patients were diag-
nosed by the age of 25 years and 80% by the age of 35. 55 subjects were
diagnosed during 1955–1989 and 52 during 1990–2015.
Acute porphyria was diagnosed commonly after the onset of acute
symptoms (Fig. 4). Acute symptoms occurred at the median age of
24 years (range 10–57 years) and the first hospitalization at the median
age of 26.5 years (range 15–57 years). At the onset of symptoms, 38%
of the women were ≤ 20 years of age.
Diagnostic delay was an average of 7.4 years (range 1–30 years)
among patients with acute symptoms. The maximal diagnostic delay
was 13.5 years (range 2–30 years) among the patients with mild to
moderate acute symptoms, implying that symptoms associated with
porphyria are not recognized. Patients treated at hospital for an acute
attack were diagnosed earlier: the mean delay was 4.4 years (range
1–22 years), and 2.9 years (range 1–12 years) for those with subsequent
attacks.
23 subjects (AIP 13, VP 10) were index cases in their families and 84
subjects (AIP 54, VP 30) were at-risk relatives. Despite earlier ver-
ification of AIP or VP in the family, 36% of at-risk family members had
acute symptoms prior to diagnosis. 21% (n = 18) had mild to moderate
acute symptoms for an average of 11 years (range 1–30 years). 5
subjects were not diagnosed until their first acute attack and 7 subjects
had already had acute attacks for an average of 1.7 years (range
0.5–8 years) prior to diagnosis, implicating that information was not
distributed effectively among family members. Altogether 41% of the
asymptomatic patients (n = 22/54) became symptomatic during the
follow-up after diagnosis (mean 9.8 years, range 0.5–34 years).
3.4. Patients' perspective on optimal timing of diagnosis
According to the patients' perspective, 41% of the subjects found the
timing of the diagnosis appropriate (Table 4). Most of them were mildly
affected or asymptomatic, and diagnosed at an early age. None of the
patients diagnosed ≤15 years of age reported being tested prematurely.
40% of the 72 patients with acute symptoms reported being diagnosed
too late. 24 (83%) of them were symptomatic prior to or at the time of
diagnosis, and 71% had been hospitalized due to one or several acute
attacks before the diagnosis.
103 (96%) subjects answered a multiple-choice questionnaire (total
111 answers) regarding the preferable age of genetic screening among
adults and children (Table 5). The majority preferred genetic screening
before puberty, after which the symptoms are more likely to occur.
None of the patients refused genetic testing, indicating that they ac-
cepted genetic screening as an important part of diagnosis in acute
porphyria.
The patients reported that confirmation of acute porphyria was
important as such (25%). This was related to a better understanding of
diverse and unspecific symptoms, minimizing the risk of misdiagnosis
(17%), and facilitating appropriate prevention of acute symptoms
(19%) by avoiding triggering factors (33%). Only 3% of the female
subjects were against genetic screening due to discrimination and the
psychological burden it might cause. 20% of the subjects did not
comment.
5% of the patients preferred testing at the symptomatic phase be-
cause they were concerned about discrimination in insurance and em-
ployment policies. Patients' symptoms were mainly the cause of dis-
crimination at work. However, exclusion of acute porphyria with
genetic testing was helpful when applying for insurance.
3.5. Benefits and disadvantages of genetic screening
42 subjects reported physical, social or psychological impairment
due to acute porphyria, the majority of whom were symptomatic (86%).
21 subjects had been hospitalized due to an acute attack, of whom 53%
had subsequent attacks. All patients with recurrent attacks reported
physical, social or psychological impairment. 14% of the subjects were
asymptomatic during the follow-up (Fig. 5).
53 subjects reported no physical, social or psychological impair-
ment, 64% of whom were symptomatic. Eighteen (34%) subjects had
been hospitalized due to an acute attack, and 61% of them had sub-
sequent attacks. Four patients had skin symptoms solely.
Table 2
Mutations and clinical characteristics in VP families (including index cases).
Mutation Outcome No. of Patients/Total Gender All acute symptoms Mild to moderate acute symptoms Acute attacks Skin symptoms
n n % F M F M F M F M F M
c. C35T p. I12T 3 12 25 7 5 2 1 2 1 – – – –
c. G338C Exon 4 skipping 2 14 14.3 10 4 2 – – – 2 – 3 –
c. C454T p. R152C 9 19 47.4 11 8 6 3 2 2 4 1 2 –
c. C454T p. R152C 7 19 36.8 13 6 5 2 2 1 3 1 6 3
c. C454T p. R152C 8 12 66.7 6 6 4 4 3 2 1 2 4 4
c. C454T p. R152C 3 11 27.3 5 6 3 – – – 3 – 1 –
c. C454T p. R152C 6 16 37.5 5 11 3 3 1 – 2 3 1 3
c. C454T p. R152C 10 17 58.8 10 7 5 5 1 – 4 5 2 3
c. C454T p. R152C 3 9 33.3 8 1 3 – 2 – 1 – 4 –
Total 51 129 75 54 33 18 13 6 20 12 23 13
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The results indicated that the patients' subjective experience of
physical, social or psychological impairment was not only due to the
activity of the disease but fear of potential symptoms and mortality.
Life-style changes such as observation of body mass index (BMI),
avoiding fasting and porphyrinogenic medications, and restricting
alcohol consumption caused additional stress. The burden of transmit-
ting an inherited disease to their offspring affected their opinion.
49 subjects (46%) reported difficulties within the health care fa-
cilities and drug administration due to acute porphyria. 81 subjects
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porphyria was insufficient, and 31 (29%) subjects reported problems
with drug administration. Porphyria dominated physicians' appoint-
ments, and patients' other complaints were neglected.
3.6. Genetic counseling
In the multi-choice questionnaire (total 123 answers), 67 (63%) of
the 107 patients preferred medical and genetic counseling at a specia-
lists' appointment. Only eight patients (7%) preferred a family doctor's
appointment. 35 patients (33%) found written information sufficient,
and only three patients (3%) found sufficient information on Finnish or
international webpages.
3.7. Benefits of genetic screening of at-risk relatives
We conducted a retrospective study concerning clinical manifesta-
tions and prognosis among at-risk family members according to the
primary method of diagnosis. Extended family screening was performed
using urinary PBG and DALA measurement together with fecal por-
phyrins and in AIP PBGD activity since 1960, and after 1990 mainly
using mutation analysis (Tables 1 and 2). All the patients received ge-
netic counseling by the time of diagnosis, related to precipitating fac-
tors and clinical manifestations of acute porphyria.
In the study group of 107 female subjects, 84 at-risk relatives (AIP
54, VP 30) were divided into two groups based on mutation (Group A)
or biochemical analysis (Group B). Index cases in the families (AIP 13,
VP 10) were excluded. Biochemical and mutation analysis was later
Fig. 3. Distribution of clinical manifestations during follow-up: A. in the study group, B. among patients with AIP, C. among patients with VP.
Table 3
Clinical manifestations of 107 female subjects with AIP and VP.
AIP VP Total AIP/VP HRa(CI)
Number of fertile follow-up years 1997 1342 3339
Asymptomatic n (%) 22 (33) 7 (18) 29 (27)
Mild to moderate acute symptoms n (%) 18 (27) 11 (27) 29 (27) 1.357 (0.573–3.213)
Single acute attack during follow-up n (%) 8 (12) 10 (25) 18 (17) 1.435 (0.761–2.705)
> 1 acute attack during follow-up n (%) 16 (24) 5 (12) 21 (19)
Recurrent attacks (≥4 attacks per year) n (%) 3 (4) – 3 (3)
Skin symptoms n (%) – 21 (53) –
Skin symptoms solely n (%) – 7 7 (7)
a HR = hazard ratio.
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available to both groups in the majority of cases (Table 6).
To predict the risk of acute symptoms, urinary PBG and DALA ex-
cretions were measured during adolescence or adulthood (1–6 analyses
per patient) (Fig. 6). Urinary PBG levels were significantly higher in
remission among AIP subjects in Group B when compared to those of
Group A, and similarly excretion of fecal protoporphyrin in VP patients
(Table 6). Half of the AIP patients with acute attacks had elevated ur-
inary PBG levels of > 100 μmol/l in remission.
3.7.1. Group A
Genetic testing was performed at a median age of 24 years (Table 6).
In Group A, 75% were asymptomatic at the time of diagnosis, and the
majority (73%) remained asymptomatic during the follow-up, which
averaged 28 years (range 6–68 years) from menarche and 12 years
(range 0–26 years) from diagnosis (Table 7). Despite genetic coun-
seling, 8 patients became symptomatic on average 11 years after di-
agnosis (range 0.5–19 years). Six of them reported mild to moderate
acute symptoms, which required no in-patient management, and two
patients were hospitalized due to acute attacks.
At genetic counseling, 10 patients (25%) had a history of acute
symptoms, mean 12 years prior to the diagnosis (range 2–27 years)
(Table 7). Two of them became asymptomatic, 8 reported continuation
of mild to moderate symptoms, but none of them had severe acute at-
tacks during the follow-up.
3.7.2. Group B
Subjects in Group B were diagnosed at a median age of 23 years, and
54% were asymptomatic at time of the diagnosis (Table 7). During the
average follow-up of 35.6 years, 54% developed acute symptoms, on
average 7 years (range 1–34 years) after the diagnosis.
45% were symptomatic at the time of diagnosis (Table 7). 11 pa-
tients had acute attacks prior to diagnosis, and 5 patients were diag-
nosed during an acute attack. Additionally, 9 patients had mild to
moderate acute symptoms a mean 9.5 years (range 1–30 years) prior to
the diagnosis. After the diagnosis, 80% of the patients remained
symptomatic, and 55% had subsequent attacks.
When Groups A and B were compared, age at the time of diagnosis
did not differ substantially. The ratio of symptomatic patients within
the study groups at the time of diagnosis was higher in Group B (45%
vs. 25%, p = .051). When adjusted for age and duration of follow-up,
the annual risk for hospitalization due to an acute attack during fertile
years was lower in Group A than Group B (0.002 vs. 0.010, p = .018).
The risk of all subsequent acute symptoms did not diminish during the
fertile follow-up years (Group A 0.017 vs. Group B 0.019, p = .640).
3.7.3. Life table analysis
According to the logistic regression model, predictors of all acute
symptoms after diagnosis, adjusted for age at diagnosis and duration of
follow-up indicated that patients who had been previously asympto-
matic at the time of the diagnosis were less likely to experience acute
symptoms during the follow-up than the symptomatic patients (OR
0.141; CI 0.044–0.490, p = .002). This was especially clear in Group A,
but the difference was not statistically significant when compared with
Group B (OR 0.327; CI 0.059–1.813, p = .201).
The cumulative risk of acute symptoms among asymptomatic pa-
tients at the time of the diagnosis was 26.7% for Group A and 58.3% for
Group B (Table 7); according to the life table analysis the hazard ratio
between Groups A/B was 0.554 (CI 0.210–1.459) (Fig. 7). The attack
risk diminished after 35 years of age. A few women experienced acute
symptoms during their menopause when hormonal alterations occur.
The cumulative risk of the first subsequent attack requiring hospi-
talization after the diagnosis among all at-risk relatives was similarly
less frequent in Group A than in Group B (OR 0.180; 95% CI
0.041–0.789, p = .041) (Fig. 8A). If subsequent attacks were followed






















Age at time of diagnosis Age at acute symptom onset
Fig. 4. Distribution of age at the time of diagnosis and onset of acute symptoms.
Table 4
Timing of the diagnosis according to clinical manifestation.
Asymptomatic Skin symptoms solely Mild to moderate acute symptoms ≥1 acute attack Median age at diagnosis (range) Total n = 107(%)
Appropriate 17 4 15 8 20 (0–76) 44 (41)
Too late 2 1 6 23 26 (13–55) 32 (30)
Too early – – – – – 0
Cannot say 9 1 8 11 25 (12–53) 29 (27)
Other – 1 – 1 – 2 (2)
Table 5
Optimal timing of genetic screening according to patients' perspective.
Patients clinical manifestations
Age of testing Asymptomatic Skin symptoms solely Mild to moderate acute symptoms ≥1 acute attack Total n = 111(%)
Prenatal 1 – 1 1 3 (3)
Newborn 9 4 7 9 29 (26)
1–5 years 5 – 8 4 17 (15)
6–10 years 1 – 3 10 14 (13)
11–14 years 9 1 4 10 24 (22)
≥15 years 4 1 5 8 18 (16)
At the symptomatic phase only 2 1 – 3 6 (5)
No genetic screening – – – – –
No answer 2 – – 2 4 (4)
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in Group A (100%) than in Group B (44%), though this was statistically
insignificant due to the small number of patients (p = .184) (Fig. 8B).
Of note, in Group B the first subsequent attack occurred mainly within
the first 5 years after the diagnosis.
4. Discussion
In this survey, we used the well-characterized Finnish patient reg-
istry including comprehensive number of patients with heterogeneous
genetic background and long follow-up time to analyze penetrance,
genetic screening and current outcome of the female patients with acute
porphyria. Female patients were chosen as a subgroup since around
90% of the symptomatic patients are currently female despite the fact
that the sex ratio of the mutation positive family members is even
[9,39,40]. Outcome of acute porphyria is highly dependent on patients'
hormonal status and symptoms occur after the onset of puberty
[14,39,41]. The personal contact during the follow-up years explains
the high response rate for the questionnaires, providing us reliable in-
formation about the patients' symptoms and well-being. The ques-
tionnaire was specially designed for AHP and not validated due to the
rarity of the disease.
4.1. Penetrance in AIP and VP
Penetrance for acute attacks was 25% for VP and 30% for AIP pa-
tients among Finnish porphyria families, which is in line with the
10–42% estimated for AIP in other countries for both sexes
[9,11,13,15,16]. In VP, the penetrance of acute attacks has shown a
decreasing tendency from 38% to 14% in Finland, especially among
men during the last three decades [9,10]. Low penetrance of acute at-
tacks (4%) has also been detected from a large family carrying the
South African major mutation (R59W) [42]. In both series, however,
penetrance of skin manifestations has been similar and more common
(30–40%) than acute symptoms suggesting different pathophysiology.
According to our study, no significant difference was detected be-
tween acute attacks of AIP or VP over six decades, but there was a
considerable variation within the Finnish families in both diseases (e.g.
10–80% in AIP; 0–50% in VP). This indicates that the individual risk for
acute symptoms depends more on sex, other modifying genes and
exogenous factors than the disease-causing mutation [3,9,43,44].
Female patients with AIP were the most frequently affected, with a
high penetrance of 41% for acute attacks and 50% for all acute symp-
toms related to porphyria. This phenomenon has also been detected
among women with a high rate of acute attacks (55%) and subsequent
attacks (39%) in the Swedish families with the major mutation
(W198X) in northern Sweden [16,39]. In addition, a high percentage
(81%) of symptomatic female patients has been reported from the pa-
tient series in USA [40]. Most acute symptoms are self-reported but
patients with acute porphyria commonly recognize porphyric symp-
toms well. Since excretion of porphyrin metabolites in the urine is often
increased more than 4-fold even in remission [9,14,20], the diagnosis of
an acute attack is clinical, mainly based on patients' reported symp-
toms, and on exclusion of other causes for complaints.
Most of the severe acute attacks among Finnish women were re-
ported before 1990's, but even after mutation analysis became common,
2.8% of the women experienced severe attacks regularly. This is in line
with the figure of 1–7.5% estimated from other European countries
based on the incidence calculations for both sexes during 2007–2009
[11,45].
4.2. Diagnostic delay
Based on our survey, the average age at the time of diagnosis was
Fig. 5. Subjects' physical, social or psychological impairment according to their
clinical manifestations of acute hepatic porphyria (AHP), n = 95.
Table 6
Demographics of groups A and B.
Group A = genetic testing
Group B = biochemical testing
Group A
n = 40
(AIP 25, VP 15)
Group B
n = 44
(AIP 29, VP 15)
P-Value
Year of diagnosis 1989–2015 1955–2012
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26 years but the range was wide, often due to family screening after an
index case. Mean age at the onset of acute symptoms was 1–2 years
earlier, indicating that many patients had already had acute symptoms
prior to the diagnosis of acute porphyria.
Patients regarded severe, often undiagnosed, acute attacks unbear-
able, and thus, many of them considered that the timing of the diag-
nosis was too late. Delay in diagnosis has often been long, 7.4 years on
average in our survey. This is mainly because clinicians have not been
acquainted with the symptoms of acute porphyria. Patients have also
avoided hospitalization due to previous negative experiences [46]. Si-
milar diagnostic challenges have also been reported from other coun-
tries with symptom onset at 20–30 years of age and diagnostic delay up
to 15 years [16,40,44]. Even repeated attacks were undiagnosed, al-
though the delay has been shorter than in single attacks. Fortunately,
early genetic screening and easy access to on-line medical databases
will improve the knowledge of porphyria among health care profes-
sionals, and patients are no longer the only source of information re-
lated to the disease.
The prevalence of acute symptoms that did not result in hospitali-
zation was surprisingly high (18%) prior to the diagnosis and has per-
sisted despite genetic counseling and avoidance behavior. Results imply
that acute porphyria-related symptoms are still unrecognized and un-
treated, although an acute attack can easily be detected by urinalysis of



































Urinary excretion of PBG and DALA in remission in Groups A and B
Fig. 6. Distribution of urinary PBG and DALA in remission, measured in Groups A and B separately among AIP and VP subjects. U-PBG normal < 9 μmol/l, U-DALA
normal < 34 μmol/l.
Table 7







Symptoms at the time of diagnosis Patients with acute symptoms during the follow-up
Group A
N = 40 (AIP 25/VP 15)
Attacka Acute symptoms Asymptomatic
Attack
N = 1 (0/1)
– 1 –
Acute symptoms
N = 9 (6/3)
– 7 2
Asymptomatic
N = 30 (19/11)
2 6 22
Group B
N = 44 (AIP 29/VP 15)
Attackb Acute symptoms Asymptomatic
Attack
N = 11 (8/3)
6 3 2
Acute symptoms
N = 9 (4/5)
5 2 2
Asymptomatic
N = 24 (17/7)
5 9 10
First subsequent attacks treated.
a 2005–2013.
b 1967–2013.
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hormonal changes, are not easy to control [41,47], they should be ac-
tively managed from the onset of symptoms to avoid progressive
manifestations of the disease. According to our patient data, sympto-
matic women typically experience acute symptoms within 35 years of
age and five years after diagnosis. Recurrent acute symptoms com-
monly result in chronic neurologic deficit and a poor quality of life
[4,46,48]. Prevention of symptoms with hormonal therapies, hemin or
givosiran, and maintaining normal weight is crucial and may stop a
patient's vicious circle [1,22].
4.3. Genetic testing
Combining targeted mutation analysis with evaluation of bio-
chemical activity is essential when identifying patients at risk for acute
attacks [25]. In primary diagnosis, mutation analysis has become the
golden standard for screening of at-risk families, which is justifiable
with a 95% sensitivity and 100% specificity, if pathogenicity of a mu-
tation (class 4 or 5) is confirmed [12,49]. Genetic testing reveals pa-
tients with mild symptoms and lower excretions of porphyrin pre-
cursors, which have been otherwise difficult to diagnose.
Biochemical analysis, especially measurement of urinary PBG has a
lower sensitivity of 84% and specificity of 71% but is the method of
choice during an acute attack, and may also have predictive value
among asymptomatic patients with AIP [12].
According to our results, urinary PBG excretion was substantially
higher in remission among patients in Group B, and acute attacks were
more frequently treated at hospital. The difference between Groups A
and B could be explained by the activity of the disease due to constant
up-regulation of ALAS1 induced by environmental factors, other mod-
ifying genes and proneness for neuropathy after the first attack.
Based on life table analysis and logistic regression model, patients
diagnosed at the asymptomatic phase have a significantly lower risk of
developing acute symptoms during their life-span. This was particularly
seen among patients diagnosed primarily with genetic testing.
Moreover, symptomatic patients diagnosed with genetic testing ex-
perienced no attacks requiring hospitalization after diagnosis, but a
substantial number described mild to moderate acute symptoms. Home-
treated attacks have become a more common pattern of management,
indicating that acute symptoms have become milder and preferably
treated at home.
Based on patients-perspectives, genetic screening should be per-
formed earlier than it currently is. Most patients preferred genetic
screening before puberty to minimize the risk of acute symptoms.
Patients' opinion on genetic testing was in general positive, although
mutation analysis verified the diagnosis of an inherited disease, which
can be transmitted to their offspring. Genetic discrimination was rare,
and mainly associated with private insurance policies among both
adults and children.
Primarily predictive genetic screening is recommended to be de-
layed until children can decide for themselves. However, genetic testing
can occur with parental consent, if testing aims at treatment or pre-
vention as in acute porphyria, where the results emphasize that early
screening of gene carriers is important for prevention of conversion to
manifest acute porphyria and severe recurrent attacks [16,50].
Considering the dramatic decrease of mortality and morbidity in
acute porphyria during the last decades due to avoidance of porphyr-
inogenic drugs and use of target treatment [9,10], we recommend
mutation analysis to be performed preferably before the age of 14 years
to identify family members at risk.
4.4. Genetic counseling
More than half of the patients reported no social, psychological or
physical impairment despite acute symptoms, emphasizing the im-
portance of patients' emotional capacity and resilience. Genetic coun-
seling was considered important, and symptomatic patients in parti-
cular preferred counseling by a specialist and written information.
Timing of counseling may vary and depend on a patient's needs and
clinical manifestations. Surprisingly, 38% of the symptomatic female
patients in our survey had already experienced acute symptoms before
21 years of age. Although adolescence may be a sensitive age, young
mutation carriers should be informed about triggering factors and the
importance of beneficial life-style changes [24]. Patients would benefit
from education and self-management of their disease, and they should
Fig. 7. Cumulative risk of all acute symptoms among patients who were asymptomatic at the time of diagnosis in Group A and B during their fertile years
(12–49 years of age).
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be aware of preventive treatment options and helpful contact possibi-
lities.
During counseling, patients' symptoms and signs should be analyzed
carefully to identify potential manifestations of acute porphyria, and to
exclude non-porphyric symptoms for their proper treatment.
Measurement of urinary porphyrin precursors provides predictive in-
formation in AIP [14], since high excretion indicates proneness for
clinical manifestations. Moreover, normal fecal excretion of
Fig. 8. Life table analysis of Group A and B. Cumulative risk of the first subsequent attack requiring hospitalization after the diagnosis A) among all at-risk relatives
and B) among patients with acute symptoms before diagnosis.
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protoporphyrins predicts no porphyric symptoms in patients with VP
[10].
5. Conclusions
Female patients with AIP were the most frequently affected, with a
high penetrance of 41% for acute attacks and 50% for all acute symp-
toms related to porphyria. Annual risk for hospitalization among VP
and AIP female patients was < 1% and for acute symptoms < 2%
during the fertile years but the risk diminished after 35 years of age.
Wide variation in penetrance was detected between families even with
similar genotypes, indicating that individual risk for acute symptoms
depends more on sex, other modifying genes and exogenous factors
than the disease-causing mutation.
Genetic screening of relatives seems to diminish the risk of severe
attacks. Diagnosis before symptom onset is key for a subject to remain
asymptomatic during the follow-up, and genetic screening should be
performed earlier than currently. Delay in diagnosis has often been long
and most patients preferred genetic screening before puberty to mini-
mize the risk of acute symptoms. During counseling, patients' symptoms
should be analyzed carefully to identify manifestations of acute por-
phyria and provide efficient treatment at the early phase of symptoms.
The prevalence of acute symptoms, which did not result in hospitali-
zation, was high and persisted despite genetic counseling and avoid-
ance behavior.
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